

Pyrazoline-Based Molecules In Antimicrobial Research: A Systematic Review

Mohd Akil¹, Abdul Rahman Khan¹, Benjamin Siddiqui, Iqbal Azad^{1*}, Naseem Ahmad¹

¹Department of Chemistry, Integral University, Lucknow - 226026

Abstract

Pyrazoline derivatives have become important compounds in medicinal chemistry because of their extensive array of biological activities, especially their antibacterial properties. The escalating problem of antimicrobial resistance (AMR) and the rising incidence of fungal infections underscore the urgent demand for new therapeutic agents. Pyrazoline derivatives, characterized by their unique five-membered heterocyclic framework, exhibit strong antibacterial and antifungal effects through mechanisms that involve interactions with microbial enzymes, DNA, and cellular membranes. Developments in synthetic methods, including environmentally friendly techniques and computational drug design, have facilitated the synthesis of derivatives with enhanced efficacy and reduced resistance. This review encapsulates recent progress in the synthesis, structural diversity, and biological efficacy of pyrazoline derivatives, emphasizing their significance in addressing global infectious disease challenges. It also reviews commercially available antimicrobial agents and the specific modifications that enhance pharmacokinetic and pharmacodynamic properties. The potential future applications of pyrazoline derivatives in combating AMR and invasive fungal infections are thoroughly examined, offering a comprehensive reference for advancing research and therapeutic innovations in this field.

INTRODUCTION

Pyrazoline derivatives have surfaced as a significant group of heterocyclic compounds in medicinal chemistry because of their extensive range of biological properties [1]. Among these effects, their antibacterial and antifungal properties have garnered considerable interest, particularly considering the pressing demand for novel therapeutic agents to address the escalating challenge of microbial resistance and fungal infections. The identification and creation of antimicrobial medications has historically depended on the structural and functional diversity of organic compounds, and pyrazoline derivatives, with their unique chemical structure, have proven to be a promising area for such research [2, 38-43].

The pyrazoline core consists of a five-membered heterocyclic ring containing two adjacent nitrogen atoms. This structural feature is not only versatile in synthetic applications but also significant in biological contexts, facilitating the development of compounds with enhanced pharmacological properties [3]. Pyrazoline derivatives are typically produced by cyclizing α,β -unsaturated carbonyl substances with hydrazines, enabling structural modifications. These modifications permit researchers to optimize the physicochemical and biological properties of the resulting molecules [4].




Figure-1: Structure of Pyrazoline

The concerning rise of antimicrobial resistance (AMR) has been recognized as one of the most urgent global health challenges of the twenty-first century. Pathogens such as multidrug-resistant *Escherichia coli*, *Staphylococcus aureus*, and *Pseudomonas aeruginosa* are becoming increasingly challenging to treat with existing therapies, leading to higher death rates, prolonged hospital stays, and rising healthcare costs [5]. Simultaneously, the incidence of invasive fungal infections caused by species like *Candida albicans*, *Aspergillus fumigatus*, and *Cryptococcus neoformans* has increased, which is often worsened by patients with weakened immune systems [6]. These developments emphasize the vital necessity for new antibacterial and antifungal therapies with innovative mechanisms of action. Pyrazoline derivatives have shown significant effectiveness against a variety of microbial and fungal infections, rendering them attractive options for drug development. The antimicrobial efficacy of these compounds is often associated with their ability to bind with bacterial and fungal cellular targets, including enzymes, DNA, and

components of the cell membrane, thereby disrupting essential physiological functions [7]. Additionally, their structural variability facilitates the exploration of different mechanisms of action, which lowers the risk of resistance emergence.

In addition to their natural biological roles, pyrazoline derivatives possess beneficial pharmacokinetic and pharmacodynamic properties, which include significant bioavailability, metabolic stability, and minimal toxicity [8]. These traits enhance their prospects as therapeutic agents. Moreover, progress in synthetic methods, including green chemistry and computational drug design, has facilitated the effective and sustainable development of pyrazoline-derived compounds featuring improved activity profiles.











Figure-2: Varied significance of Pyrazoline and its derivatives [44-46]

This review will offer a thorough overview of existing studies concerning pyrazoline derivatives used as antibacterial and antifungal agents. It will examine the synthesis and structural differences of these compounds, their mechanisms of action, and the spectrum of their biological activities. Furthermore, the review will investigate recent progress, challenges, and future perspectives in this field, emphasizing the role of pyrazoline derivatives in alleviating the global impact of infectious diseases. By merging current knowledge and pointing out research deficiencies, this review seeks to encourage upcoming research and advancements in the creation of pyrazoline-based treatments.

Table-1: Some Marketed Drugs for Anti-Bacterial Activity

S. No.	Marketed Drug	Structure	Reference
1.	Cefoselis		[47]
2.	Ceftolozane		[48]
3.	Ciprofloxacin		[49]
4.	Piperacillin		[50]

5.	Levonadifloxacin		[51]
6.	Amoxicillin		[52]
7.	Azithromycin		[53]
8.	Meropenem		[54]
9.	Doxycycline		[55]
10.	Clarithromycin		[56]
11.	Metronidazole		[57]
12.	Vancomycin		[58]

13.	Clindamycin		[59]
14.	Gentamicin		[60]
15.	Erythromycin		[61]
16.	Nitrofurantoin		[62]
17.	Tigecycline		[63]
18.	Tedizolid		[64]
19.	Fosfomycin		[65]






















20.	Rifampicin		[66]
-----	------------	---	------

Table-2: Some Marketed Drugs for Anti-Fungal Activity

S. No.	Marketed Drug	Structure	Reference
1.	Fluconazole		[67]
2.	Itraconazole		[68]
3.	Ketoconazole		[69]
4.	Voriconazole		[70]
5.	Posaconazole		[71]


6.	Caspofungin		[72]
7.	Micafungin		[73]
8.	Anidulafungin		[74]
9.	Griseofulvin		[75]
10.	Terbinafine		[76]
11.	Naftifine		[77]
12.	Clotrimazole		[78]

13.	Efinaconazole		[79]
14.	Tavaborole		[80]
15.	Ciclopirox		[81]
16.	Tolnaftate		[82]
17.	Amorolfine		[83]
18.	Flucytosine		[84]
19.	Nystatin		[85]
20.	Amphotericin B		[86]

Routes of Synthesis Pyrazoline Derivatives

In 2020, Xu et al. [9] reported a silver-catalyzed protocol for synthesizing 5-aryl-3-trifluoromethylpyrazoles via the coupling of N'-benzylidene tolylsulfonohydrazides with ethyl 4,4,4-trifluoro-3-oxobutanoate. The reaction sequence proceeds through nucleophilic attack, intramolecular cyclization, dehydrobenzenesulfonyl elimination,

and a final [1,5]-hydrogen shift, affording the desired trifluoromethylpyrazoles in moderate to good yields. Optimization studies revealed that raising the temperature to 60°C improved yields, whereas higher temperatures led to decreased product formation. Among catalysts, Cu (OTf)₂ afforded a 60% yield, while Fe(OTf)₃ was ineffective. Toluene proved superior to THF and dioxane as the solvent. For bases, K₂CO₃ outperformed NaH, t-BuOK, and t-BuONa. Notably, the combination of neocuproine as a ligand with a silver catalyst provided the best result, delivering yields exceeding 99%, whereas 2,2'-bipyridine and 1,10-phenanthroline gave 57% and 92% yields, respectively.




Scheme-1: Synthesis of 5-aryl-3-trifluoromethyl pyrazoles utilizing a silver catalyst

Table-3: Structural Modification to synthesized pyrazole derivative by Xu et al.

Structure	Modification (R)
	H
	4-Me
	4-tBu
	4-O-CH ₂ Ph
	4-OMe
	4-N(Me) ₂
	3-CF ₃
	4-CN
	4-F
	2,4-diF
	(2-F, 5-Br)
	4-Cl
	4-Br
	2-Br


In 2020, Kim et al. [10] developed a rapid and efficient "one-pot" strategy for synthesizing pyrazoles from (hetero)arenes and carboxylic acids. The method involves the in situ formation of ketones and β -diketones, followed by heterocyclization with hydrazine. The underlying concept was that three simple steps could yield 3,5-disubstituted pyrazoles. Initially, a TfOH/TFAA-mediated "one-pot" synthesis of 1,3-diketones was accomplished from methylarylketones, utilizing arenes and carboxylic acids. The resulting dicarbonyl intermediates were subsequently converted into 3,5-disubstituted pyrazoles under Knorr reaction conditions.




Scheme-2: The synthetic method for producing pyrazoles from arenes and carboxylic acids through a one-pot synthesis

Table-4: Structural Modification to synthesized pyrazole derivative by Kim et al.

Modifications	Structure
R	Ar


Me	Ph	
t-BuCH ₂	3,4-diMePh	
1-AdCH ₂	2,4-diClPh	
3-HO-1- AdCH ₂	4-OMePh	
	Thiophenyl	
	5-Br-Thiophenyl	
	5-(dibenzo[b,d]furan-2-yl)	

In 2020, Komendantova et al. [11] reported a novel approach for the synthesis of 3,4-dicarbonyl-substituted pyrazoles. The reaction employs 1,3-dicarbonyl compounds and oxamic acid thiohydrazides in the presence of catalytic TsOH, followed by sulfur elimination. The process proceeds via an iodine-accelerated imination/halogenation/cyclization/ring-contraction sequence. Using readily available substrates and mild conditions, this method provides a straightforward and highly efficient strategy for the synthesis of functionalized pyrazoles.




Scheme-3: Production of substituted pyrazoles from 1,3-diketones and hydrazine derivatives

Table-5: Structural Modification to synthesized pyrazole derivative by Komendantova et al.


Modifications			Structure
R ₁	R ₂	R ₃	
Alk	Alk	Alk	
Ar	OAlk	Ar	
Bn		Het	
		Bn	

In 2020, Gerus et al. [12] investigated the fluorination of enones using XeF₂ in the presence of BF₃·Et₂O. The inclusion of pyridine in the reaction mixture afforded fluoroenones in a 68% yield. Subsequent treatment of fluoroenones with hydrazine sulfate produced fluoropyrazoles in an excellent 87% yield.



Scheme-4: Synthesis of fluoropyrazole by Gerus et al., [12]

In 2020, Stephan et al. [13] developed a versatile strategy for synthesizing pyrazole derivatives. Initially, a Heck reaction between (hetero) aryl bromides and acrolein or vinyl ketones generated 3-(hetero)aryl propenals and propenones. The reaction was performed under Jeffery's and Fu's conditions with Beller's CataCXium PtB ligand. The resulting 3-substituted α,β -unsaturated carbonyl compounds served as key intermediates for the preparation of 3,5-diarylpyrazoles and 3-(hetero)aryl pyrazoles via consecutive three- and pseudo-four-component reactions, providing low to good yields. This flexible approach is suitable for constructing diverse pyrazole libraries.



Scheme-5: Synthesis of pyrazole derivative by Stephan et al., [13]

Table-6: Structural Modification to synthesized pyrazole derivative by Stephan et al.

Modifications		Structure
R	Ar	
H	Ph	
Me	4-FPh	
Ph	4-CNPh	
4-OMePh	4-NMe ₂ Ph	
4-NMe ₂ Ph	4-CF ₃ Ph	
Pentyl	4-OMePh	
	3-F,4-OMePh	
	2-OMePh	
	2-thiophenyl	

In 2020, Tian et al. [14] reported a transition-metal-free synthesis of 4-sulfonyl pyrazoles through a tandem C(sp²)-H sulfonylation/pyrazole annulation process. The reaction involves N,N-dimethyl enaminones and sulfonyl hydrazines, catalyzed by molecular iodine at room temperature in the presence of TBHP and NaHCO₃. This method provides an efficient and straightforward route to sulfonyl-substituted pyrazoles.



Scheme-6: Synthetic pathways for pyrazole derivatives utilizing I₂/TBHP, NaHCO₃ as a catalyst.

Table-7: Structural Modification to synthesized pyrazole derivative by Tian et al.

Modifications		Structure
R	Ar	
4-OMe	4-ClPh	
4-NMe ₂	3,5-diClPh	
3-Cl	4-OMePh	
	4-FPh	
	4-ClPh	
	4-BrPh	
	2-ClPh	

In 2020, Bhaskaran et al. [15] developed a metal-free protocol for synthesizing pyrazoles and chromeno-pyrazoles from aldehydic hydrazones and acetylenic esters. The method accommodates both symmetrical and unsymmetrical hydrazones and alkynes, affording a wide range of products in moderate to very high yields.




Scheme-7: Synthesis of pyrazole derivatives by Bhaskaran et al., [15]

Table-8: Structural Modification to synthesized pyrazole derivative by Bhaskaran et al.

Modifications			Structure
R ₁	R ₂	Ar	
CO ₂ Et	H	Ph	
CO ₂ Me	CO ₂ Et	4-OMePh	
	CO ₂ Me	4-BrPh	
	Ph	4-FPh	
		2-BrPh	

In 2020, Li et al. [16] explored the 1,3-dipolar cycloaddition of N-tosylhydrazones with acetylene gas using a simple balloon setup. Screening of bases and solvents identified K_2CO_3 as the most effective base. The reaction provided pyrazoles in reasonable to good yields, with DMSO performing better than NMP for reactions involving ketone-derived N-tosylhydrazones. This straightforward method holds promise for commercial applications.




Scheme-8: Synthesis of pyrazole derivatives by Li et al., [16]

Table-9: Structural Modification to synthesized pyrazole derivative by Li et al.

Modifications (Ar)	Structure
Ph	
4-MePh	
3-MePh	
2-MePh	
4-NMe ₂ Ph	
2-OMePh	
4-OMePh	
4-CF ₃ Ph	
4-BrPh	
3-BrPh	

In 2020, Ledovskaya et al. [17] achieved a regioselective synthesis of 1,3-disubstituted pyrazoles via 1,3-dipolar cycloaddition of vinyl ethers with hydrazoneyl chlorides, promoted by triethylamine (TEA) as a mild base.




Scheme-9: Synthesis of pyrazole derivatives by Ledovskaya et al., [17]

Table-10: Structural Modification to synthesized pyrazole derivative by Ledovskaya et al.

Modifications		Structure
Ar ₁	Ar ₂	
Ph	Ph	
4-MePh	4-MePh	
4-OMePh	4-BrPh	
	4-FPh	

In 2020, Lakeland et al. [18] reported a visible-light photoredox-catalyzed approach for synthesizing 1,4-disubstituted pyrazoles using $Ru(bpy)_3(PF_6)_2$ as the catalyst. The method exhibited excellent yields and broad substrate scope.




Scheme-10: Synthesis of pyrazole derivatives by Lakeland et al., [18]

Table-11: Structural Modification to synthesized pyrazole derivative by Lakeland et al.

Modifications		Structure
R	Ar	
Butyl	H	
iPr	4-OMePh	
Cyclohexyl	4-CNPh	
Me	4-FPh	
Ph	4-ClPh	
Benzyl	4-BrPh	
TBSO-Butyl	4-CF ₃ Ph	
(CH ₂) ₂ CO ₂ Me	3-MePh	
(CH ₂) ₂ CO ₂ N(OMe)Me		

In 2020, Pearce et al. [19] developed a multicomponent oxidative coupling strategy to access multi-substituted pyrazoles. The reaction involves the combination of alkynes, nitriles, and titanium imido complexes, proceeding through diazatitana-cyclohexadiene intermediates and a 2-electron oxidation pathway mediated by TEMPO.




Scheme-11: Synthesis of pyrazole derivatives by Pearce et al., [19]

Table-12: Structural Modification to synthesized pyrazole derivative by Pearce et al.

Modifications			Structure
R ₁	R ₂	R ₃	
Ph	Me	Me	
4-Me-Ph	Et	Et	
4-MeOPh	Ph	4-BuPh	
4-CF ₃ -Ph	4-BuPh		
IPr			
Me			

In 2021, Devi et al. [20] designed an elegant method for synthesizing functionalized pyrazole chalcones and indenyl-pyrazoles through a 1,3-dipolar cycloaddition of α -diazo phosphonates, sulfones, and trifluoromethanes with 2,4,6-trisubstituted pyrylium tetrafluoroborate salts. The reaction proceeds via nucleophilic addition to pyrylium salts, base-catalyzed ring opening, and intramolecular 1,5-cyclization, yielding 1,3-dipolar cycloaddition products. Subsequent hydride reduction and Nazarov-type cyclization, followed by acidic workup, afforded the target molecules in high yields. This strategy offers an efficient route to bioactive pyrazole derivatives.




Scheme-12: Synthesis of pyrazole derivatives by Devi et al., [20]

Table-13: Structural Modification to synthesized pyrazole derivative by Devi et al.

Modifications			Structure
R ₁	R ₂	X	

Ph	Ph	SO ₂ Ph	
4-OMePh	4-OMePh	Tsyl	
4-MePh	4-MePh	CF ₃	
4-ClPh	3-OMePh		
	3-ClPh		

In 2021, Zhao et al. [21] investigated cascade reactions of alkyl α -diazoesters with yrones catalyzed by Al(OTf)₃, enabling the efficient synthesis of a series of 4-substituted pyrazoles. The transformation proceeds via a [3 + 2] cycloaddition, followed by 1,5-ester shift, 1,3-hydrogen shift, and N-H insertion steps. Mechanistic insights were obtained through deuterium labeling, kinetic studies, and control experiments, providing valuable data for understanding the underlying reaction pathways.




Scheme-13: Synthesis of pyrazole derivatives by Zhao et al., [21]

Table-14: Structural Modification to synthesized pyrazole derivative by Zhao et al.

Modifications			Structure
R ₁	R ₂	Ar	
Me	Me	Ph	
Ph	Et	4-FPh	
		4-MePh	
		4-ClPh	
		4-BrPh	
		4-CF ₃ Ph	
		CO ₂ MePh	

In 2021, Chen et al. [22] developed a transition-metal-free protocol under mild conditions for synthesizing disulfonated pyrazoles from sulfonyl hydrazides, 1,3-diketones, and sodium sulfinate using molecular iodine as the catalyst. The reaction proceeds via the in situ generation of sulfonyl iodide from sodium sulfinate and iodine, followed by imine formation (from sulfonyl hydrazides and 1,3-diketones), tautomerization to an enol form, and nucleophilic attack of the sulfonyl iodide, culminating in intramolecular condensation to afford the desired pyrazoles in a single step.




Scheme-14: Synthesis of pyrazole derivatives by Chen et al., [22]

Table-15: Structural Modification to synthesized pyrazole derivative by Chen et al.

Modifications			Structure
R ₁	R ₂	R ₃	

Ph	Me	Ts	
4-MePh	'Bu		
4-PhPh	n-C ₅ H ₁₁		
Naphthyl	Ph		
4-'BuPh	4-MePh		
3-MePh	4-OMePh		
4-OMePh	Naphthyl		
4-FPh	4-FPh		
4-BrPh	4-BrPh		
4-ClPh	4-ClPh		
4-IPh	3-ClPh		
	3-Thiophenyl		
	2-Furanyl		
	2-Pyridinyl		

In 2022, Yang et al. [23] introduced a novel metal-oxo-cluster-based inorganic framework, described as a 3D platelike ternary-oxo-cluster (NaCoMo), which serves as a highly efficient catalyst for the condensation and cyclization of 1,3-diketones with sulfanylhydrazides to yield pyrazoles. This method achieved excellent yields (up to 99%) under mild conditions. The development of NaCoMo opens avenues for utilizing non-classical polyoxometalates in pyrazole synthesis.




Scheme-15: Synthesis of pyrazole derivatives by Yan et al., [23]

Table-16: Structural Modification to synthesized pyrazole derivative by Yan et al.

Modifications			Structure
R ₁	R ₂	R ₃	
H	H	Me	
Me	Cl	Cyclopropyl	
OMe	Me		
Cl			
Br			
NO ₂			

In 2022, Liu et al. [24] reported the catalytic application of a Keggin-based U(VI)-containing polytungstate (U-POW) tetramer (U4), which exhibits bifunctional Lewis acid-base properties. Under mild conditions, U4 efficiently catalyzed the reaction of various hydrazines with 1,3-diketones to produce pyrazoles in high yields. This work not only highlights the potential of actinide-containing polyoxometalates (POMs) in catalytic synthesis but also represents the first example of a U-POW tetramer applied to pyrazole synthesis.




Scheme-16: Synthesis of pyrazole derivatives by Liu et al., [24]

Table-17: Structural Modification to synthesized pyrazole derivative by Liu et al.

Modifications		Structure
R ₁	R ₂	

H	Ph	
Me	Pentyl	
Cl	PhCO	
	4-MePhCO	
	4-OMePhCO	
	4-FPhCO	
	4-ClPhCO	
	4-BrPhCO	

In 2022, Kula et al. [25] investigated the reaction mechanisms involving (E)-3,3,3-trichloro-1-nitroprop-1-ene and N-(4-bromophenyl)-C-arylnitrylimine, providing insights into the structural and electronic factors governing the formation of substituted pyrazoles.




Scheme-17: Synthesis of pyrazole derivatives by Kula et al., [25]

Table-18: Structural Modification to synthesized pyrazole derivative by Kula et al.

Modifications (R)	Structure	
H Cl OMe		

Anti-Microbial Activity

In 2017, Afaq et al. [26] reported that glacial acetic acid (GAA) promoted the thermal cyclization of hydrazine hydrate with 1,6-diphenylhexa-1,5-diene-3,4-dione, affording five pyrazoline derivatives (1a-e) in high yields (70-87%). Antibacterial evaluation showed inhibition zones (mm) against *Escherichia coli* (11.5, 12.0, 12.0, 7.5, and 16.0 mm) and *Staphylococcus aureus* (13.0, 13.5, 14.0, 8.0, and 18.0 mm). Compound 1e, bearing OCH₃ and OH groups, exhibited the strongest antibacterial activity.




Scheme-18: Synthesis of derivatives of bi-pyrazoline (1a - 1e)


Table-19: Structural Modifications of Synthesized Compound 1

Synthesized Compound	Compound Name	R ₁	R ₂
	1a	H	H
	1b	H	CH ₃
	1c	H	OCH ₃
	1d	H	Cl
	1e	OCH ₃	OH

In 2019, Fariana Nur Santi et al. [27] synthesized a new pyrazoline derivative (2) and evaluated its toxicity and antibacterial properties. The brine shrimp lethality test (BSLT) yielded an LC₅₀ of 96.96 ppm, indicating potential anticancer activity. The compound demonstrated moderate to significant antibacterial effects against *S. aureus* ATCC 25923 and *E. coli* ATCC 25922 by the agar diffusion method.

Scheme-19: Synthesis of pyrazoline derivative exhibiting potential Anti-Bacterial activity against *S. aureus* and *E. coli*


In 2020, Mohammad Asad et al. [28] synthesized five N-trifluoroacetyl-2-pyrazolines (3a-e) via the cyclization of chalcones with hydrazine and trifluoroacetic acid, achieving yields of 72-79%. Among them, 3a (bearing a NO₂ group) exhibited strong antibacterial activity, with MICs of 79 µM for *Pseudomonas aeruginosa* and 90 µM for *E. coli*. SEM analysis revealed complete bacterial membrane rupture upon treatment.




Scheme-20: Synthesis of N-trifluoroacetyl-2-pyrazoline derivatives (3a - 3e)

Table-20: Structural Modifications of Synthesized Compound 3

Synthesized Compound	Compound Name	R
	3a	
	3b	



In 2020, Dileep Kumar Achutha et al. [29] synthesized thiophene-tethered pyrazoline carbothioamide derivatives (4a–k) via an eco-friendly 3 + 2 annulation of chalcones and thiosemicarbazide hydrochloride in aqueous citrus extract. Antioxidant studies revealed DPPH and hydroxyl radical scavenging activity, while 4c and 4k showed notable antibacterial activity against *S. aureus* (20 and 15 μ g/mL), *E. coli* (15 and 15 μ g/mL), *B. subtilis* (25 and 20 μ g/mL), and antifungal activity against *A. niger*, *A. flavus*, and *C. albicans*.




Scheme-21: Synthesis of pyrazoline derivatives (4a – 4k) via thiophene-tethered pyrazoline carbothioamide

Table-21: Structural Modifications of Synthesized Compound 4

Synthesized Compound	Compound Name	R ₁	R ₂	R ₃
	4a	H	H	H
	4b	H	H	F
	4c	H	H	Cl
	4d	H	H	CH ₃
	4e	H	H	OCH ₃
	4f	H	H	NO ₂
	4g	H	H	N(CH ₃) ₂
	4h	H	H	Br
	4i	CH ₃	H	CH ₃
	4j	H	OCH ₃	OCH ₃
	4k	Cl	H	Cl

In 2021, Matthew Payne et al. [30] developed a one-pot oxidative cyclization of chalcones with hydrazine monohydrate, producing fifteen 3,5-diaryl-1H-pyrazoles (5a–q) with yields ranging from 10–90%. 5p, possessing OCH₃ and OH groups, exhibited significant antibacterial activity against *S. aureus* (MIC = 8 μ g/mL) and altered *B. subtilis* morphogenesis before cell lysis, without cytotoxic effects on 3T3-L1 mammalian cells.




Scheme-22: Synthesis of potential anti-bacterial agents of 3,5-diaryl-1H-pyrazole derivatives (5a - 5q)

Table-22: Structural Modifications of Synthesized Compound 5

Synthesized Compound	Compound Name	R ₁	R ₂	R ₃	R ₄	R ₅
	5a	p-ClPh	H	OCH ₃	OCH ₃	H
	5b	p-ClPh	H	OCH ₃	H	OCH ₃
	5c	p-ClPh	OCH ₃	H	H	OCH ₃
	5d	p-ClPh	H	OCH ₃	H	H
	5e	p-ClPh	H	OBn	H	H
	5f	p-ClPh	H	H	OBn	H
	5g	p-ClPh	H	OBn	OCH ₃	H
	5h	p-C(CH ₃) ₃ Ph	H	OCH ₃	H	H
	5i	p-C(CH ₃) ₃ Ph	OCH ₃	H	H	OCH ₃
	5j	p-C(CH ₃) ₃ Ph	H	OCH ₃	OCH ₃	H
	5k	p-C(CH ₃) ₃ Ph	H	OBn	H	H
	5l	Ph	H	OCH ₃	H	H
	5m	Ph	OCH ₃	H	H	OCH ₃
	5n	Ph	H	OCH ₃	OCH ₃	H
	5o	tert-Bu	H	OH	OCH ₃	H
	5p	Ph	H	OH	OCH ₃	H
	5q	Ph	H	H	OH	H

Also in 2021, Mohammad Asad et al. [31] synthesized three N-acyl-2-pyrazolines (6a-c) by cyclizing chalcones with hydrazine hydrate in the presence of aliphatic acids, yielding 78-84%. Compound 6b showed the best antibacterial activity (MIC: *S. aureus* & *E. coli* = 32 µg/mL; *S. pyogenes* & *S. typhimurium* = 64 µg/mL).




Scheme-23: Synthesis of pyrazoline derivatives (6a - 6c) as N-acyl-2-pyrazolines

Table-23: Structural Modifications of Synthesized Compound 6

Synthesized Compound	Compound Name	R ₁	R ₂	A
	6a			CH ₃ COOH
	6b			CH ₃ CH ₂ COOH
	6c			CH ₃ CH ₂ CH ₂ COOH

In 2021, Lokesh Kumar et al. [32] employed 1,3-dipolar cycloaddition between pyrazoline-linked alkynes and 2-bromo-N-aryacetamide to synthesize pyrazoline-amide-1,2,3-triazole hybrids (7a-d) in 64–82% yields. 7a–c exhibited potent antibacterial and antifungal activity (MIC = 0.062–0.078 μ mol/mL), with molecular dynamics simulations confirming 7a as the most promising antibacterial candidate.




Scheme-24: Synthesis of pyrazoline derivatives (7a – 7d)

Table-24: Structural Modifications of Synthesized Compound 7

Synthesized Compound	Compound Name	R ₁
	7a	H
	7b	CH ₃
	7c	OCH ₃
	7d	Br

In 2021, Pathade et al. [33] described an eco-friendly PEG-400-mediated synthesis of pyrazoline derivatives (8a–d), which demonstrated antibacterial activity against *S. aureus*, *B. subtilis*, *E. coli*, and *P. vulgaris* (zones \geq 15–20 mm, comparable to chloramphenicol) and antifungal activity against *A. niger* and *C. albicans* (zones \geq 15–20 mm, comparable to amphotericin-B).




Scheme-25: Synthesis of pyrazoline derivatives (8a – 8d)

Table-25: Structural Modifications of Synthesized Compound 8

Synthesized Compound	Compound Name	R ₁	R ₂	R ₃	R ₄
	8a	H	OCH ₃	OCH ₃	H
	8b	Cl	H	Cl	H
	8c	H	OCH ₃	OCH ₃	OCH ₃
	8d	H	H	F	H

In 2021, Deepashree Nagaraj et al. [34] synthesized N-dimethylaminophenyl-substituted pyrazoline carbothioamide derivatives (9a-g) via a 3 + 2 cycloaddition of chalcones and hydrazinecarbothioamide hydrochloride with amberlyst-15. Compounds 9a, 9b, and 9g showed strong antibacterial activity against *S. aureus*, *E. coli*, and *B. subtilis* at low MICs, surpassing ciprofloxacin in some cases. However, 9e and 9g, bearing methoxy substituents, showed no significant activity even at 100 µg/mL.




Scheme-26: Synthesis of pyrazoline derivatives (9a - 9g)

Table-26: Structural Modifications of Synthesized Compound 9

Synthesized Compound	Compound Name	R ₁	R ₂
	9a	H	H
	9b	H	F
	9c	H	Cl
	9d	H	CH ₃
	9e	OCH ₃	H
	9f	H	OCH ₃
	9g	OCH ₃	OCH ₃

In 2023, Padhy et al. [35] synthesized pyrazolone derivatives (10a-d) by fusing benzimidazole chalcones with hydrazine hydrate, producing hybrids with antibacterial and anticancer activities. Compounds 10a (GI₅₀ = 26.13 µM) and 10c (GI₅₀ = 12.27 µM) showed significant cytotoxicity against the MDA-MB-231 breast cancer cell line.




Scheme-27: Synthesis of pyrazolone derivatives (10a - 10d)

Table-27: Structural Modifications of Synthesized Compound 10

Synthesized Compound	Compound Name	R
	10a	H
	10b	CH ₃
	10c	Cl
	10d	Br

In 2023, Kumar et al. [36] prepared pyrazoline derivatives (11a-i) from chalcones and phenyl hydrazine. Compounds 11b, 11f, and 11h displayed notable antibacterial activity against *Shigella* sp., *B. subtilis*, *S. typhi*, and *S. aureus*. Additionally, 11h exhibited significant antifungal activity against *C. albicans* and *A. fusarium*.




Scheme-28: Synthesis of pyrazoline derivatives (11a - 11i)

Table-28: Structural Modifications of Synthesized Compound 11

Synthesized Compound	Compound Name	R
	11a	H
	11b	3-NO ₂
	11c	4-NO ₂
	11d	4-NH ₃
	11e	4-OCH ₃
	11f	4-CH ₃
	11g	4-Cl
	11h	4-OH
	11i	4-CH ₂ CH ₃

In 2023, Finally, Daryan O. Ali et al. [37] synthesized azo-benzylxy-pyrazoline hybrids (12a-j) via the Michael addition of azo-benzylxy chalcones with phenylhydrazine. The compounds exhibited moderate antibacterial activity against *S. aureus* and *E. coli* at 200–1000 ppm, compared to azithromycin as a standard.



Scheme-29: Synthesis of pyrazoline derivatives (12a - 12j)

Table-29: Structural Modifications of Synthesized Compound 12

Synthesized Compound	Compound Name	R
	12a	H
	12b	2-Cl
	12c	2-F
	12d	4-Cl
	12e	4-F
	12f	OCH ₃
	12g	CH ₃
	12h	4-NO ₂
	12i	4-PhOCH ₂
	12j	4-ClPhOCH ₂

CONCLUSION

Pyrazoline derivatives represent a highly promising category of molecules within the realm of medicinal chemistry, especially due to their antibacterial characteristics. Their structural versatility, combined with the simplicity of synthetic alterations, has facilitated the creation of derivatives exhibiting enhanced antibacterial and antifungal effects. These compounds demonstrate significant efficacy against a diverse array of pathogens, including multidrug-resistant bacterial strains and invasive fungal species, through mechanisms that target vital cellular components and functions. Innovations in synthetic methods, such as green chemistry and catalytic systems, have expanded the potential for producing compounds with improved pharmacological profiles and reduced toxicity. Regardless of these advancements, customizing these molecules for clinical use continues to pose a challenge, particularly concerning selectivity, bioavailability, and resistance to microbial defences. This review underscores the importance of ongoing investigation into pyrazoline derivatives as possible solutions to the urgent global challenge of infectious diseases. Pyrazoline derivatives hold substantial promise for the advancement of next-generation antimicrobial agents as they tackle existing limitations and pursue innovative strategies.

Declaration: This manuscript has Integral University Manuscript Communication Number: IU/R&D/2025-MCN0003864.

Author Contributions:

Mohd Akil: Resources, Writing-original draft preparation

Abdul Rahman Khan: Data Curation, Visualization, Writing-original draft

Iqbal Azad: Resources, Supervision, Writing-Review & Editing

Naseem Ahmad: Supervision, Writing-original draft, Supervision, Formal Analysis

Conflict of Interest: The authors declare no competing interests.

Ethical Approval: Not applicable.

Consent to Participate: All authors have agreed to participate.

Consent to Publish: All authors agree upon publication of the present paper.

REFERENCE

1. Sallam, E. R., Aboulnaga, S. F., Samy, A. M., Beltagy, D. M., El Desouky, J. M., Abdel-Hamid, H., & Fetouh, H. A. (2023). Synthesis, characterization of new heterocyclic compound: pyrazolyl hydrazino quinoxaline derivative: 3-[5-(hydroxyethyl)-1-phenylpyrazol-3-yl]-2-[2, 4, 5-trimethoxybenzylidene] hydrazonyl-quinoxaline of potent antimicrobial, antioxidant, antiviral, and antitumor activity. *Journal of Molecular Structure*, 1271, 133983.
2. Breijeh, Z., & Karaman, R. (2023). Design and synthesis of novel antimicrobial agents. *Antibiotics*, 12(3), 628.
3. Ríos, M. C., & Portilla, J. (2022). Recent advances in synthesis and properties of pyrazoles. *Chemistry*, 4(3), 940-968.
4. Matiadis, D. (2023). Strategies and Methods for the Synthesis of 2-Pyrazolines: Recent Developments (2012–2022). *Advanced Synthesis & Catalysis*, 365(12), 1934-1969.
5. Ferrara, F., Castagna, T., Pantolini, B., Campanardi, M. C., Roperti, M., Grotto, A., ... & Langella, R. (2024). The challenge of antimicrobial resistance (AMR): current status and future prospects. *Naunyn-Schmiedeberg's Archives of Pharmacology*, 1-13.
6. Casadevall, A. (2022). Immunity to invasive fungal diseases. *Annual review of immunology*, 40(1), 121-141.
7. Patinote, C., Cirnat, N., Bonnet, P. A., & Deleuze-Masquéfa, C. (2021). Fused Azolo-Quinoxalines: Candidates for Medicinal Chemistry. A Review of their Biological Applications. *Current Medicinal Chemistry*, 28(4), 712-749.

8. Selatnia, I., Khamaysa, O. M. A., Soliman, A. G., Bourzami, R., Sid, A., Lgaz, H., ... & Bensouici, C. (2024). Mechanistic insights and therapeutic implications of novel pyrazoline derivatives on antioxidant and enzymatic inhibitory activities. *Journal of Molecular Structure*, 1296, 136761.
9. Xu, Y., Chen, Q., Tian, Y., Wu, W., You, Y., & Weng, Z. (2020). Silver-catalyzed synthesis of 5-aryl-3-trifluoromethyl pyrazoles. *Tetrahedron Letters*, 61(5), 151455.
10. Kim, J. K., Gong, M., Shokova, E. A., Tafeenko, V. A., Kovaleva, O. V., Wu, Y., & Kovalev, V. V. (2020). Pyrazoles: 'one-pot' synthesis from arenes and carboxylic acids. *Organic & Biomolecular Chemistry*, 18(29), 5625-5638.
11. Komendantova, A. S., Lyssenko, K. A., Zavarzin, I. V., & Volkova, Y. A. (2020). Iodine-promoted synthesis of pyrazoles from 1, 3-dicarbonyl compounds and oxamic acid thiohydrazides. *Organic Chemistry Frontiers*, 7(13), 1640-1646.
12. Gerus, I. I., Zhuk, Y. I., Kacharova, L. M., Röschenthaler, G. V., Shaitanova, E. N., Sorochinskii, A. E., ... & Wojcik, J. (2020). Uncommon fluorination of enones with xenon difluoride. *Journal of Fluorine Chemistry*, 229, 109413.
13. Stephan, M., Panther, J., Wilbert, F., Ozog, P., & Müller, T. J. (2020). Heck Reactions of Acrolein or Enones and Aryl Bromides-Synthesis of 3-Aryl Propenals or Propenones and Consecutive Application in Multicomponent Pyrazole Syntheses. *European Journal of Organic Chemistry*, 2020(14), 2086-2092.
14. Tian, L., Wan, J. P., & Sheng, S. (2020). Transition Metal-free C–H Sulfonylation and Pyrazole Annulation Cascade for the Synthesis of 4-Sulfonyl Pyrazoles. *ChemCatChem*, 12(9), 2533-2537.
15. Bhaskaran, R. P., Janardhanan, J. C., & Babu, B. P. (2020). Metal-Free Synthesis of Pyrazoles and Chromenopyrazoles from Hydrazones and Acetylenic Esters. *ChemistrySelect*, 5(16), 4822-4825.
16. Li, D., Qiu, S., Chen, Y., & Wu, L. (2020). K2CO3-Promoted Pyrazoles Synthesis from 1, 3-Dipolar Cycloaddition of N-Tosylhydrazones with Acetylene Gas. *ChemistrySelect*, 5(38), 12034-12037.
17. Ledovskaya, M. S., Voronin, V. V., Polynski, M. V., Lebedev, A. N., & Ananikov, V. P. (2020). Primary Vinyl Ethers as Acetylene Surrogate: A Flexible Tool for Deuterium-Labeled Pyrazole Synthesis. *European Journal of Organic Chemistry*, 2020(29), 4571-4580.
18. Lakeland, C. P., Watson, D. W., & Harrity, J. P. (2020). Exploiting synergistic catalysis for an ambient temperature photocycloaddition to pyrazoles. *Chemistry—A European Journal*, 26(1), 155-159.
19. Pearce, A. J., Harkins, R. P., Reiner, B. R., Wotal, A. C., Dunscomb, R. J., & Tonks, I. A. (2020). Multicomponent pyrazole synthesis from alkynes, nitriles, and titanium imido complexes via oxidatively induced N–N bond coupling. *Journal of the American Chemical Society*, 142(9), 4390-4399.
20. Devi, L., Sharma, G., Kant, R., Shukla, S. K., & Rastogi, N. (2021). Regioselective synthesis of functionalized pyrazole-chalcones via a base mediated reaction of diazo compounds with pyrylium salts. *Organic & Biomolecular Chemistry*, 19(18), 4132-4136.
21. Zhao, P., Zeng, Z., Feng, X., & Liu, X. (2021). Multisubstituted pyrazole synthesis via [3+ 2] cycloaddition/rearrangement/NH insertion cascade reaction of α -diazoesters and ynones. *Chinese Chemical Letters*, 32(1), 132-135.
22. Chen, J., Chen, D., Kuang, J., & Ma, Y. (2021). Transition Metal-Free De Novo Synthesis of Sulfonated Pyrazoles from Sulfonyl Hydrazides, 1, 3-Diketones, and Sodium Sulfinates at Room Temperature. *The Journal of Organic Chemistry*, 86(14), 9289-9298.
23. Yang, G., Liu, Y., Lin, X., Ming, B., Li, K., & Hu, C. (2022). Self-assembly of a new 3D platelike ternary-oxo-cluster: An efficient catalyst for the synthesis of pyrazoles. *Chinese Chemical Letters*, 33(1), 354-357.
24. Liu, Y. F., Li, K., Lian, H. Y., Chen, X. J., Zhang, X. L., & Yang, G. P. (2022). Self-assembly of a U (VI)-containing polytungstate tetramer with lewis acid-base catalytic activity for a dehydration condensation reaction. *Inorganic Chemistry*, 61(50), 20358-20364.
25. Kula, K., Łapczuk, A., Sadowski, M., Kras, J., Zawadzka, K., Demchuk, O. M., ... & Jasiński, R. (2022). On the question of the formation of nitro-functionalized 2, 4-pyrazole analogs on the basis of nitrylimine molecular systems and 3, 3, 3-trichloro-1-nitroprop-1-ene. *Molecules*, 27(23), 8409.
26. Sabah, A. A. T. H. H., & Abbas, A. F. (2017). Synthesis, Characterization and Antibacterial Activity of Some New 5, 5'-diphenyl-4, 4', 5, 5'-tetrahydro-1H, 1'H-3, 3'-bipyrazole Derivatives. *Synthesis*, 9(8).
27. Santi, F. N., Nur, Y., Agung Rahmadani, H., & Kuncoro, H. (2019). Synthesis and Bioactivity of New Pyrazoline Derivative: N-carbamido-3-(2, 4-dichlorophenyl)-5-(4-hydroxy-3-methoxyphenyl) pyrazoline. *Research Journal of Chemistry and Environment Vol*, 23, 12.
28. Asad, M., Arshad, M. N., Oves, M., Khalid, M., Khan, S. A., Asiri, A. M., ... & Dzudzevic-Cancar, H. (2020). N-Trifluoroacetylated pyrazolines: Synthesis, characterization and antimicrobial studies. *Bioorganic chemistry*, 99, 103842.
29. Achutha, D. K., Vagish, C. B., Renuka, N., Lokeshwari, D. M., & Kariyappa, A. K. (2020). Green synthesis of novel pyrazoline carbothioamides: A potent antimicrobial and antioxidant agents. *Chemical Data Collections*, 28, 100445.
30. Payne, M., Bottomley, A. L., Och, A., Asmara, A. P., Harry, E. J., & Ung, A. T. (2021). Synthesis and biological evaluation of 3, 5-substituted pyrazoles as possible antibacterial agents. *Bioorganic & medicinal chemistry*, 48, 116401.
31. Asad, M., Khan, S. A., Arshad, M. N., Asiri, A. M., & Rehan, M. (2021). Design and synthesis of novel pyrazoline derivatives for their spectroscopic, single crystal X-ray and biological studies. *Journal of Molecular Structure*, 1234, 130131.
32. Kumar, L., Lal, K., Kumar, A., Paul, A. K., & Kumar, A. (2021). Pyrazoline tethered 1, 2, 3-triazoles: Synthesis, antimicrobial evaluation and in silico studies. *Journal of Molecular Structure*, 1246, 131154.
33. Pathade, S. S., Adole, V. A., & Jagdale, B. S. (2021). PEG-400 mediated synthesis, computational, antibacterial and antifungal studies of fluorinated pyrazolines. *Current Research in Green and Sustainable Chemistry*, 4, 100172.
34. Nagaraj, D., Nagamallu, R., & Kariyappa, A. K. (2021). Design, Synthesis, Spectroscopic Characterization of New Pyrazole Carbothioamides as Antifungal and Antibacterial Candidates.
35. Padhy, G. K., Rath, D., Bhukta, P., Kumar, L. A., Sethy, K., Panda, J., ... & Behera, A. K. (2023). Synthesis Of Novel Benzimidazole-Pyrazoline Hybrid Molecules As Antibacterial And Anticancer Agent. *Journal of Pharmaceutical Negative Results*, 521-526.
36. Kumar, C., Manjunatha, S., & Nandeshwarappa, B. (2023). Synthesis of novel pyrazolic analogues of chalcones as potential antibacterial and antifungal agents. *Current Chemistry Letters*, 12(3), 613-622.
37. Ali, D. O., & Hawaiz, F. E. (2023). A stepwise synthetic approach and antibacterial assessment of some new pyrazoline derivatives containing azo and benzyloxy moieties. *Zanco Journal of Pure and Applied Sciences*, 35(1), 165-176.

38. Yan, R., Huang, X., Deng, X., & Song, M. (2022). Synthesis and activity evaluation of some pyrazole-pyrazoline derivatives as dual anti-inflammatory and antimicrobial agents. *Polycyclic Aromatic Compounds*, 42(8), 5006-5019.

39. AksÖz, B. E., GÜrpınar, S. S., & Eryilmaz, M. (2020). Antimicrobial activities of some pyrazoline and hydrazone derivatives. *Turkish Journal of Pharmaceutical Sciences*, 17(5), 500.

40. TN, M. M., Snigdha, K., Asiri, A. M., Sobahi, T. R., & Asad, M. (2023). Green synthesis of chromonyl chalcone and pyrazoline as potential antimicrobial agents-DFT, molecular docking and antimicrobial studies. *Journal of Molecular Structure*, 1271, 133993.

41. Desai, N. C., Vaja, D. V., Monapara, J. D., Manga, V., & Vani, T. (2021). Synthesis, biological evaluation, and molecular docking studies of novel pyrazole, pyrazoline-clubbed pyridine as potential antimicrobial agents. *Journal of Heterocyclic Chemistry*, 58(3), 737-750.

42. Dias, B. B., da Silva Dantas, F. G., Galvão, F., Cupozak-Pinheiro, W. J., Wender, H., Pizzuti, L., ... & de Oliveira, K. M. P. (2020). Synthesis, structural characterization, and prospects for new cobalt (II) complexes with thiocarbamoyl-pyrazoline ligands as promising antifungal agents. *Journal of Inorganic Biochemistry*, 213, 111277.

43. Elewa, S. I., Mansour, E., Nassar, I. F., & Mekawey, A. A. (2020). Synthesis of some new pyrazoline-based thiazole derivatives and evaluation of their antimicrobial, antifungal, and anticancer activities. *Russian Journal of Bioorganic Chemistry*, 46, 382-392.

44. Abou-Zied, H. A., Beshr, E. A., Hayallah, A. M., & Abdel-Aziz, M. (2024). Emerging insights into pyrazoline motifs: A comprehensive exploration of biological mechanisms and prospects for future advancements. *Journal of Molecular Structure*, 1296, 136807.

45. Ravindar, L., Hasbullah, S. A., Rakesh, K. P., & Hassan, N. I. (2023). Pyrazole and pyrazoline derivatives as antimalarial agents: A key review. *European Journal of Pharmaceutical Sciences*, 183, 106365.

46. Ravindar, L., Hasbullah, S. A., Rakesh, K. P., & Hassan, N. I. (2023). Pyrazole and pyrazoline derivatives as antimalarial agents: A key review. *European Journal of Pharmaceutical Sciences*, 183, 106365.

47. Chen, J., Liu, Y., Jia, W., Xu, X., Sun, G., Wang, T., ... & Liu, Y. (2023). In Vitro Activities of Aztreonam-Avibactam, Eravacycline, Cefoselis, and Other Comparators against Clinical Enterobacteriales Isolates: a Multicenter Study in China, 2019. *Microbiology Spectrum*, 11(3), e04873-22.

48. Lizza, B. D., Betthauser, K. D., Ritchie, D. J., Micek, S. T., & Kollef, M. H. (2021). New perspectives on antimicrobial agents: ceftolozane-tazobactam. *Antimicrobial agents and chemotherapy*, 65(7), 10-1128.

49. Shariati, A., Arshadi, M., Khosrojerdi, M. A., Abedinzadeh, M., GanjaliShahi, M., Maleki, A., ... & Khoshnood, S. (2022). The resistance mechanisms of bacteria against ciprofloxacin and new approaches for enhancing the efficacy of this antibiotic. *Frontiers in public health*, 10, 1025633.

50. Eman, I., Fahmy, E. K., Esmaeel, S. E., Elkattaway, H. A., & Hegazy, W. A. (2024). A review on recent analytical methodologies developed for the micro-determination of piperacillin in different matrices. *Microchemical Journal*, 111203.

51. Appalaraju, B., Baveja, S., Baliga, S., Shenoy, S., Bhardwaj, R., Kongre, V., ... & Bhagwat, S. (2020). In vitro activity of a novel antibacterial agent, levonadifloxacin, against clinical isolates collected in a prospective, multicentre surveillance study in India during 2016-18. *Journal of Antimicrobial Chemotherapy*, 75(3), 600-608.

52. Lemnaru, G. M., Trușcă, R. D., Ilie, C. I., Țiplea, R. E., Ficai, D., Oprea, O., ... & Dițu, L. M. (2020). Antibacterial activity of bacterial cellulose loaded with bacitracin and amoxicillin: In vitro studies. *Molecules*, 25(18), 4069.

53. Heidary, M., Ebrahimi Samangani, A., Kargari, A., Kiani Nejad, A., Yashmi, I., Motahar, M., ... & Khoshnood, S. (2022). Mechanism of action, resistance, synergism, and clinical implications of azithromycin. *Journal of clinical laboratory analysis*, 36(6), e24427.

54. Abed, M., & Yousuf, S. (2021). A Review on Meropenem. *Research Journal of Pharmacy and Technology*, 14(9), 5034-5038.

55. Carneiro, B. T., Prado, M. M. D., Nogueira, I. D. O., Moreira, A. N., & André, C. B. (2024). Exploring the effectiveness of doxycycline in restorative dentistry: a systematic review of in vitro studies. *Odontology*, 1-27.

56. Qin, Y., Sun, M., Zhang, N., Yang, Y., & Ma, P. (2022). Synthesis and biological evaluation of antibacterial activity of novel clarithromycin derivatives incorporating 1, 2, 3-triazole moieties at the 4" and 11-OH positions. *Bioorganic Chemistry*, 127, 106020.

57. Giacomazzo, G. E., Conti, L., Fagorzi, C., Pagliai, M., Andreini, C., Guerri, A., ... & Giorgi, C. (2023). Ruthenium (II) Polypyridyl Complexes and Metronidazole Derivatives: A Powerful Combination in the Design of Photoresponsive Antibacterial Agents Effective under Hypoxic Conditions. *Inorganic Chemistry*, 62(20), 7716-7727.

58. Perveen, S., Zhai, R., Chen, X., Kanwal, T., Shah, M. R., Lu, M., ... & Jin, M. (2024). Synthesis of high-performance antibacterial agent based on incorporated vancomycin into MOF-modified lignin nanocomposites. *International Journal of Biological Macromolecules*, 274, 133339.

59. Jia, Y., Zhang, Y., & Zhu, H. (2023). Structure-Activity Relationship Target Prediction Studies of Clindamycin Derivatives with Broad-Spectrum Bacteriostatic Antibacterial Properties. *Molecules*, 28(21), 7357.

60. Karunaratna, I., Gunasena, P., Gunathilake, S., & De Alvis, K. (2024). The clinical use of gentamicin: Indications, mechanism of action, and key considerations.

61. Cao, Z., Zheng, W., Huang, M., Yao, X., Zhu, W., Sheng, L., ... & Zhu, C. (2023). Synthesis and antibacterial activity of erythromycin 9-acylhydrazone derivatives. *Medicinal Chemistry*, 19(6), 586-593.

62. Mahdizade Ari, M., Dashtbin, S., Ghasemi, F., Shahroodian, S., Kiani, P., Bafandeh, E., ... & Darbandi, A. (2023). Nitrofurantoin: properties and potential in treatment of urinary tract infection: a narrative review. *Frontiers in cellular and infection microbiology*, 13, 1148603.

63. Yaghoubi, S., Zekiy, A. O., Krutova, M., Gholami, M., Kouhsari, E., Sholeh, M., ... & Maleki, F. (2022). Tigecycline antibacterial activity, clinical effectiveness, and mechanisms and epidemiology of resistance: narrative review. *European Journal of Clinical Microbiology & Infectious Diseases*, 1-20.

64. Iqbal, K., Milioudi, A., & Wicha, S. G. (2022). Pharmacokinetics and pharmacodynamics of tedizolid. *Clinical Pharmacokinetics*, 61(4), 489-503.

65. Aljeldah, M. M., Yassin, M. T., Mostafa, A. A. F., & Aboul-Soud, M. A. (2023). Synergistic antibacterial potential of greenly synthesized silver nanoparticles with fosfomycin against some nosocomial bacterial pathogens. *Infection and Drug Resistance*, 125-142.

66. Rinaldi, F., Hanieh, P. N., Sennato, S., De Santis, F., Forte, J., Fraziano, M., ... & Carafa, M. (2021). Rifampicin-liposomes for *Mycobacterium abscessus* infection treatment: Intracellular uptake and antibacterial activity evaluation. *Pharmaceutics*, 13(7), 1070.

67. Ramírez-Carmona, W., Fernandes, G. L. P., Diaz-Fabregat, B., Oliveira, E. C., do Prado, R. L., Pessan, J. P., & Monteiro, D. R. (2023). Effectiveness of fluconazole as antifungal prophylaxis in cancer patients undergoing chemotherapy, radiotherapy, or immunotherapy: systematic review and meta-analysis. *APMIS*, 131(11), 668-684.

68. Li, C. L., Fang, Z. X., Wu, Z., Hou, Y. Y., Wu, H. T., & Liu, J. (2022). Repurposed itraconazole for use in the treatment of malignancies as a promising therapeutic strategy. *Biomedicine & Pharmacotherapy*, 154, 113616.

69. Al-Otaibi, H. F., Alharthi, A. H., Alshonqeeti, A. E., ALanazi, D. T., Alowais, S. A., & Al-Qadhi, M. A. (2024). Controlled Delivery of Ketoconazole an Antifungal Agent from Uncemented Titanium Using a Layer-by-Layer Technique. *ACS omega*, 9(46), 46519-46529.

70. Zimmer, D., Frasier, K., Li, V., Loperfito, A., Mukarram, M., Miller, L., ... & Vinagolu-Baur, J. (2024). Unraveling the Dual Role of Voriconazole as an Antifungal Agent and Precursor to Squamous Cell Carcinoma. *Journal of Cancer*, 12(2), 21-30.

71. Gupta, A. K., Talukder, M., & Venkataraman, M. (2022). Review of the alternative therapies for onychomycosis and superficial fungal infections: posaconazole, fosravuconazole, voriconazole, oteseconazole. *International Journal of Dermatology*, 61(12), 1431-1441.

72. Su, S., Yan, H., Min, L., Wang, H., Chen, X., Shi, J., & Sun, S. (2022). The antifungal activity of caspofungin in combination with antifungals or non-antifungals against *Candida* species in vitro and in clinical therapy. *Expert Review of Anti-infective Therapy*, 20(2), 161-178.

73. Marena, G. D., dos Santos Ramos, M. A., Bauab, T. M., & Chorilli, M. (2021). Biological properties and analytical methods for micafungin: a critical review. *Critical Reviews in Analytical Chemistry*, 51(4), 312-328.

74. Shen, S., Zhang, Y., Yin, Z., Zhu, Q., Zhang, J., Wang, T., ... & Deng, F. (2022). Antiviral activity and mechanism of the antifungal drug, anidulafungin, suggesting its potential to promote treatment of viral diseases. *BMC medicine*, 20(1), 359.

75. Bai, Y. B., Zhang, M., Li, D., Zhao, Y., Huang, L. Z., & Gao, J. M. (2023). Synthesis and antifungal activity of derivatives of the natural product griseofulvin against phytopathogenic fungi. *Journal of Agricultural and Food Chemistry*, 71(16), 6236-6248.

76. Dwiecki, P. M., Michalak, T. K., & Muszalska-Kolos, I. (2022). Assessment of the properties of terbinafine hydrochloride and the search route for antifungal agents. *Journal of Molecular Structure*, 1252, 132225.

77. Trailokya, A. A., Shirsat, A. B., Madhu, R., & Shah, B. (2023). Naftifine: A Topical Allylamine for Superficial Dermatophytosis. *J. Assoc Physicians India*, 71(5), 11-12.

78. Meneses, M. L., Recalde, M., Martin, P. L., & Pardo, A. G. (2022). Antifungal activity of silver nanoparticles and clotrimazole against *Candida* spp. *Brazilian Journal of Pharmaceutical Sciences*, 58, e18719.

79. Gupta, A. K., Mann, A., Polla Ravi, S., Wang, T., & Cooper, E. A. (2024). Efinaconazole 10% solution: a comprehensive review of its use in the treatment of onychomycosis. *Expert Opinion on Pharmacotherapy*, 25(15), 1983-1998.

80. He, Z., Huang, D. C., Guo, D., Deng, F., Sha, Q., Zhang, M. Z., ... & Gu, Y. C. (2023). Synthesis, fungicidal activity and molecular docking studies of tavaborole derivatives. *Advanced Agrochem*, 2(2), 185-195.

81. Mucha, P., Borkowski, B., Erkiet-Polgj, A., & Budzisz, E. (2024). Ciclopirox and Ciclopirox Olamine: Antifungal Agents in Dermatology with Expanding Therapeutic Potential. *Applied Sciences*, 14(24), 11859.

82. Khairy, M., & Khorshed, A. A. (2020). Inspection of electrochemical behavior of tolnaftate a topical antifungal agent and its active hydrolysis products by disposable screen-printed carbon electrode. *Journal of Electroanalytical Chemistry*, 871, 114274.

83. Madhu, R. (2021). TOPICAL ANTIFUNGAL DRUGS-AN OVERVIEW. *Indian Journal of Practical Pediatrics*, 23(1), 22.

84. Sigera, L. S. M., & Denning, D. W. (2023). Flucytosine and its clinical usage. *Therapeutic advances in infectious disease*, 10, 20499361231161387.

85. Sousa, F., Nascimento, C., Ferreira, D., Reis, S., & Costa, P. (2023). Reviving the interest in the versatile drug nystatin: A multitude of strategies to increase its potential as an effective and safe antifungal agent. *Advanced Drug Delivery Reviews*, 199, 114969.

86. Cavassin, F. B., Baú-Carneiro, J. L., Vilas-Boas, R. R., & Queiroz-Telles, F. (2021). Sixty years of amphotericin B: an overview of the main antifungal agent used to treat invasive fungal infections. *Infectious Diseases and Therapy*, 10(1), 115-147.